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In research of the last decade, rhythmic (circadian) variations of vascular endothelial growth factor (VEGF) production by tumors were 
discovered. The present paper authors have earlier synthesized and characterized a new derivative photosensitizer — an immunoconjugate 
of hematoporphyrin with antiVEGF antibodies. Aim: To elaborate and to test a novel modification of the photodynamic therapy of tumors 
(PDT) method, founding upon a timed introduction of the immunoconjugated photosensitizer to tumor-bearing animals, so that this 
coincides with a maximum content of VEGF in tumor tissues. Methods: Circadian variations of VEGF contents in murine transplanted 
tumors, Lewis lung carcinoma and sarcoma 180, were determined by ELISA method. Immunoconjugated photosensitizer concentrations 
in tumors were estimated by spectrofluorometry. Photoirradiation of the tumors was carried out with a red light (wavelength of 635 nm) 
from a semiconductor laser. Light doses were chosen, calculating on a partial inhibition of tumor growth, in order that a dependence 
of PDT efficiency on a daily time-moment (circadian rhythm phase) of the treatment could be observed distinctly. Results: Circadian 
variations of the VEGF levels in Lewis lung carcinoma and sarcoma 180 were demonstrated with the maximum at 14:00 h and the mini-
mum at 02:00 h. Intra-abdominal introduction into tumor-bearing mice of the immunoconjugated photosensitizer resulted in a greater 
accumulation of the immunoconjugate in tumors at 14:00 h than at 02:00 h. Laser irradiation of carcinomas and sarcomas 
at 14:00 h or 02:00 h after introduction of the immunoconjugated photosensitizer to mice the day before at the same time points, induced 
a significantly enhanced inhibition of tumor growth in animals treated at day-time versus those treated at night-time. Conclusion: The 
obtained results justify further attempts to transfer principles of tumor chronochemotherapy onto photodynamic therapy.
Key words: circadian rhythm, circadian rhythm-guided PDT, chronotherapy, immunoconjugated hematoporphyrin, antibodies 
to vascular endothelial growth factor.
Photodynamic therapy of tumors (PDT), a com-
paratively new, modern method of cancer treatment, 
has a remarkable set of merits such as a considerable 
selectivity of antitumor effects, a low invasiveness and 
an absence of serious side reactions. However, due 
to a poor penetration of light radiation into biological 
tissues, the method practical application is rather 
limited, and radical curative results with it are feasible 
only in early stages of cancer, in tumors with a superfi-
cial type of growth, and so on. To partly overcome the 
drawback, efforts are undertaken to synthesize com-
bined photosensitizers containing antibodies or other 
biologically active agents (peptides, growth factors, 
cytokines, etc) more or less specific for malignant 
cells [1, 2]. Such photosensitizers are better accumu-
lated in tumor tissues, making them responsive even 
to a scarce light that penetrates into a tumor depth.
Another way to obtain photosensitizers, targeted 
to a site of tumor growth, is to conjugate them with an-
giogenic elements of vessels that are actively formed 
in a growing tumor. In particular, the conjugates of pho-
tosensitizers with factors (inductors) of angiogenesis 
or antibodies to them can be created. In this context, 
our attention was drawn to the observations in which 
rhythmic (circadian) character of a secretion by tu-
mors of a vascular endothelial growth factor (VEGF) 
was established [3]. Since earlier we synthesized 
and characterized a conjugate of hematoporphyrin 
with antiVEGF as the means to enhance transporta-
tion of the photosensitizer into tumors [4, 5], we now 
explored a possibility to raise efficiency of PDT with 
this immunoconjugated photosensitizer by timing its 
introduction in tumor-bearing animals relatively to the 
circadian rhythm of VEGF secretion by tumors.
MATERIALS AND METHODS
Circadian variations of VEGF production were 
studied in mice with transplanted tumors — Lewis 
lung carcinoma and sarcoma 180. Two month old 
male mice, bred in the animal facility of R.E. Kavetsky 
Institute of Experimental Pathology, Oncology and 
Radiobiology, NAS of Ukraine, were utilized. All animal 
procedures were carried out according to the rules 
of local Ethic Committee and were approved by the 
Ethic Board of IEPOR NASU. The tumors were ex-
cised during 24 hours at four different time points: 
at 08:00 h, 14:00 h, 20:00 h and 02:00 h. VEGF from 
tumor samples was isolated and evaluated for the fac-
tor concentration and specifity by ELISA method using 
recombinant VEGF-165 (Sigma, USA) and monoclonal 
antiVEGF antibodies (Sigma, USA) as described in [6].
To synthesize the combined photosensitizers, 
antibodies to VEGF were conjugated to hematopor-
phyrin dihydrochloride (Fluka, Netherlands) emploing 
1-ethyl-3(3-dimethylaminopropyl)-carbodiimide-HCl 
as a linker [7]. Molar ratio of anti-VEGF antibodies 
to hematoporphyrin in the immonoconjugate was 
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estimated spectrophotometrically by absorption 
at 280 nm and 505 nm, respectively.
To ascertain that accumulation of the hematopor-
phyrin-antiVEGF in tumors obeys circadian rhythmic-
ity, the immunoconjugated photosensitizer or free 
hematoporphyrin (in a parallel control group) were 
injected to mice intra-abdominally, 3 mg per mouse 
of the immunoconjugate and 0.05 mg per mouse of the 
free photosensitizer, so that doses of hematoporphyrin 
were in both cases equal. Photosensitizer contents 
in samples were determined by a hematoporphyrin 
fluorescence (λmax 620, 680 nm, fluorospectrometer 
Nanodrop 3300, USA) in tumor tissue samples after 
their freezing in liquid nitrogen, mechanical homogeni-
zation and extraction with a methanol-water solution.
For circadian rhythm-guided PDT, two tumor models 
of different histological origin were used: metastasiz-
ing Lewis lung carcinoma, transplanted into a foot pad 
of C57Bl/6 mice, and non-metastasizing sarcoma 180, 
transplanted under the skin of white outbred mice. The 
therapy started when carcinomas reached a diameter 
of 5–7 mm and sarcomas — 10 mm. The conjugated 
photosensitizer (3.0 mg/mouse) or free hematoporphy-
rin (0.05 mg/mouse) were introduced intra-abdominally 
at 14:00 h or 02:00 h, that is at time points of a maximum 
and minimum accumulation of the immunoconjugated 
photosensitizer, respectively, as it was preliminarily estab-
lished by experiments on determination of circadian varia-
tions in the VEGF production, described above. In 24 hours 
after the photosensitizer introduction, tumors were treated 
with red-light radiation (wavelength of 635 nm, power 
density of 26 mW/cm2, dose of 30 J/cm2) from a semi-
conductor laser (Photonika Plus, Ukraine). A treatment 
efficiency was estimated by excised tumor masses (Lewis 
carcinoma) or by tumor sizes on the second, ninth and 12th 
days after animal photoirradiation (sarcoma 180).
In all three series of animal experiments (on deter-
mination of a rhythmicity in the VEGF production /I/ and 
in the immunoconjugated photosensitizer accumula-
tion /II/, as well as on the circadian rhythm-guided 
PDT /III/), before every experiment was started, mice 
were kept under continuous darkness for two weeks, 
so that a free-running circadian rhythm set in. Then, 
the regimen was switched to an alternation of light 
and darkness (light from 08:00 h to 20:00 h, darkness 
from 20:00 h to 08:00 h), and under these conditions 
animals remained until the end of the experiment.
All the experiments were performed in autumnal 
season (October — November).
For all data calculations the statistical t-test was used.
RESULTS AND DISCUSSION
Circadian variations of the VEGF content in tumors. 
VEGF concentrations were determined for 24 h at four 
different time points in the samples of tumor tissues, ob-
tained from mice with Lewis lung carcinoma or sarcoma 
180. As a result, regular circadian fluctuations of the an-
giogenic factor production were observed: a maximum 
content of the factor in tumors fell on the middle of the 
day-time and a minimum — on the middle of night (Fig. 1).
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Fig. 1. Circadian variations of the VEGF content in sarcoma 180 and 
Lewis lung carcinoma. Data for every time point are presented as the 
mean ± SD of three animals
Circadian character of the immunoconjugated 
photosensitizer accumulation. The immunoconju-
gated photosensitizer hematoporphyrin-antiVEGF was 
introduced to mice intra-abdominally at two different 
time points: at 14:00 h or 02:00 h. Next day, at the 
same time points, tumor samples were obtained, and 
the accumulated photosensitizer fluorescence was 
measured by spectrofluorometry. Fluorograms, pre-
sented in Fig. 2 and 3, show higher fluorescence levels 
(and therefore, elevated photosensitizer accumulation) 
at the time of VEGF production maximum (at 14:00 h), 
in comparison with its minimum (at 02:00 h).
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Fig. 2. Immunoconjugated photosensitizer fluorescence in Lew-
is carcinoma as a function of daily time-points (circadian rhythm 
phases) exploited for the photosensitizer introduction/analysis
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Fig. 3. Immunoconjugated photosensitizer fluorescence in sar-
coma 180 as a function of daily time-points (circadian rhythm 
phases) exploited for the photosensitizer introduction/analysis
Circadian rhythm-guided photodynamic therapy. 
Proceeding from the data on circadian variations of VEGF 
production by tumors and on a synchronism of this 
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process with hematoporphyrin-antiVEGF accumulation 
in tumor tissues, we carried out experiments on a rhythm-
guided PDT of Lewis carcinoma and sarcoma 180, using 
the immunoconjugated photosensitizer. Parameters 
of laser irradiation were chosen in anticipation of a partial 
inhibition of tumor growth, so that a dependence of PDT 
efficiency on a daily time-moment (circadian rhythm 
phase) of the treatment could be observed distinctly.
As it is shown in Fig. 4, PDT treatment of mice with 
carcinomas on a middle of the day-time (at 14:00 h), that 
is at the time of the maximum in VEGF content, resulted 
in significantly (p < 0.05) greater tumor growth inhibition 
than the same treatment executed at 02:00 h of night 
which corresponded to the time of the minimum in VEGF 
content of tumor tissues. In the group of animals, 
treated at the day-time, growth inhibition made 60.4% 
comparing to control (untreated) animals, and in the 
group with the night-time treatment it amounted to 45%.
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Fig. 4. Circadian rhythm-guided PDT of Lewis carcinoma with 
application of the immunoconjugated photosensitizer.
*The difference is significant as compared to both control and 
02:00 h groups (p < 0.05)
Since in studies on the circadian rhythm-guided PDT 
with another experimental tumor — sarcoma 180 treat-
ment efficiency was evaluated by a tumor size, there 
was a possibility to follow the tumor growth dynamics. 
In Fig. 5 the data obtained in these experiments are 
presented. As it is seen from the data, tumor growth in-
hibition was again considerably more pronounced in the 
group of mice, treated at 14:00 h. Virtually, tumors in this 
group were not growing for whole the observation period.
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Fig. 5. Circadian rhythm-guided PDT of sarcoma 180 with application 
of the immunoconjugated photosensitizer.
*The difference is significant as compared to both control and 
02:00 h groups (p < 0.05).
Thus, presented results apparently corroborate our 
assumption that PDT application of the immunocon-
jugated photosensitizer hematoporphyrin-antiVEGF, 
timed with the maximum in circadian variations of the 
VEGF content in tumors, may open a fresh opportunity 
for enhancing the therapy effectiveness. Although 
chronobiological approaches to the chemotherapy 
of tumors were already recognized for quite a long 
time [8–10], such chronotherapeutic modifications 
of PDT have not been, to our knowledge, proposed 
before. Only very recently we have formulated basic 
principles of the method which may be designated 
as a chronophotodynamic therapy of tumors [11]. 
The promising results obtained in our study justify 
further attempts to extend the principles of antitumor 
chronochemotherapy to PDT. Moreover, so far as the 
conjugated photosensitizers development is on the 
rise, it probably makes sense to expand the research 
scope, not confining it to the VEGF or angiogenic fac-
tors in general.
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